GFLG peptide

GFLG peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Batch to batch variation of the purity

H-GFLG-OH

H-Gly-Phe-Leu-Gly-OH

4

95.37%

C₁₉H₂₈N₄O₅

392.45

Synthetic

Powder

GLFG oligopeptides exhibit specific sensitivity towards the enzyme cathepsin B that helps effective controlled release of cargo molecules in the cytoplasm. It serves as an enzyme-cleavable linker in drug delivery systems. With its unique property, it can conjugate with drugs and remain stable during transportation in the blood. This linker is highly specific to certain enzymes, such as cathepsin B, which is often up-regulated in tumor cells. When the conjugate reaches the tumor site with a high concentration of the specific enzyme, the GFLG peptide can be cleaved, leading to the release of the conjugated drug. This targeted drug release mechanism allows for enhanced therapeutic efficacy and reduced side effects on normal tissues. The GFLG peptide's ability to control drug release makes it a valuable component in the development of novel and efficient drug delivery strategies, especially in cancer treatment.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides

• Song SJ, Choi JS. Enzyme-Responsive Amphiphilic Peptide Nanoparticles for Biocompatible and Efficient Drug Delivery. Pharmaceutics. 2022 Jan 7;14(1):143. doi: 10.3390/pharmaceutics14010143. PMID: 35057039; PMCID: PMC8779831.
• Zhang C, Pan D, Li J, Hu J, Bains A, Guys N, Zhu H, Li X, Luo K, Gong Q, Gu Z. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy. Acta Biomater. 2017 Jun;55:153-162. doi: 10.1016/j.actbio.2017.02.047. Epub 2017 Mar 2. PMID: 28259838.

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.